An update on angiogenesis targeting in head and neck squamous cell carcinoma.
Angiogenesis
Bevacizumab
EGFR
HNSCC
Monoclonal antibodies
TKI
VEGF
VEGFR
Journal
Cancers of the head & neck
ISSN: 2059-7347
Titre abrégé: Cancers Head Neck
Pays: England
ID NLM: 101703807
Informations de publication
Date de publication:
2020
2020
Historique:
received:
24
10
2019
accepted:
04
03
2020
entrez:
14
4
2020
pubmed:
14
4
2020
medline:
14
4
2020
Statut:
epublish
Résumé
Angiogenesis is an integral aspect of the growth and proliferation of solid tumors, including head and neck squamous cell carcinoma (HNSCC), and has potential implications in prognosis and treatment of both localized and recurrent/metastatic HNSCC. Therefore, there has been a significant interest in utilizing anti-angiogenic agents either alone or in combination with currently approved and emerging therapies. A phase III randomized trial (E1305) of chemotherapy with or without bevacizumab in the first-line treatment of recurrent/metastatic HNSCC showed an increased response rate and longer progression-free survival but fell short in demonstrating a statistically significant improved survival with bevacizumab. Moreover, toxicity, especially bleeding, was increased. Nevertheless, the study of other anti-angiogenic agents and novel combinations with other therapies, including immunotherapy, remains of interest. Several clinical trials are currently underway.
Identifiants
pubmed: 32280512
doi: 10.1186/s41199-020-00051-9
pii: 51
pmc: PMC7132887
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
5Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Oral Oncol. 2014 Jan;50(1):19-26
pubmed: 24269532
Head Neck. 2016 Apr;38 Suppl 1:E566-70
pubmed: 25784616
Clin Cancer Res. 2005 Feb 15;11(4):1434-40
pubmed: 15746043
Lancet. 2019 Jun 15;393(10189):2404-2415
pubmed: 31079938
J Exp Clin Cancer Res. 2012 Apr 26;31:37
pubmed: 22538017
Invest New Drugs. 2015 Dec;33(6):1248-56
pubmed: 26453566
Ann Oncol. 2016 Aug;27(8):1594-600
pubmed: 27177865
Oncol Lett. 2016 Sep;12(3):2127-2132
pubmed: 27602151
Oral Oncol. 2015 May;51(5):409-15
pubmed: 25680863
N Engl J Med. 2006 Feb 9;354(6):567-78
pubmed: 16467544
J Clin Oncol. 2020 Apr 10;38(11):1154-1163
pubmed: 31961766
J Clin Oncol. 2019 Dec 1;37(34):3266-3274
pubmed: 31618129
Nature. 1993 Apr 29;362(6423):841-4
pubmed: 7683111
J Clin Oncol. 2007 Aug 20;25(24):3766-73
pubmed: 17704426
Oral Oncol. 2013 Aug;49(8):835-41
pubmed: 23727257
J Clin Oncol. 2006 Jun 10;24(17):2666-72
pubmed: 16763281
Cancer J. 2011 Sep-Oct;17(5):267-72
pubmed: 21952273
Invest New Drugs. 2010 Oct;28(5):677-83
pubmed: 19649772
J Clin Oncol. 2007 Jun 1;25(16):2171-7
pubmed: 17538161
Cancer Cell. 2008 Mar;13(3):206-20
pubmed: 18328425
Ann Oncol. 2011 Oct;22(10):2304-9
pubmed: 21330337
J Clin Oncol. 2000 May;18(10):2046-52
pubmed: 10811669
J Thorac Oncol. 2017 Feb;12(2):194-207
pubmed: 27729297
Cancer Chemother Pharmacol. 2010 Mar;65(4):649-60
pubmed: 19655144
Am J Transl Res. 2015 Oct 15;7(10):1675-98
pubmed: 26692917
N Engl J Med. 2008 Sep 11;359(11):1116-27
pubmed: 18784101
Nature. 2011 May 19;473(7347):298-307
pubmed: 21593862
Br J Cancer. 2000 Sep;83(6):775-81
pubmed: 10952783
J Clin Oncol. 2010 Jul 10;28(20):3330-5
pubmed: 20498388
J Clin Oncol. 2011 Mar 20;29(9):1140-5
pubmed: 21343546
Oncol Rep. 2007 Jul;18(1):47-51
pubmed: 17549344
Cancer. 2012 Oct 15;118(20):5008-14
pubmed: 22415650
J Clin Oncol. 2008 Apr 1;26(10):1732-41
pubmed: 18375903
J Clin Oncol. 2010 Jan 1;28(1):21-8
pubmed: 19917865
Nature. 2007 Dec 6;450(7171):825-31
pubmed: 18064003
Lancet Oncol. 2018 Aug;19(8):1082-1093
pubmed: 30001987
Int J Cancer. 2012 Feb 15;130(4):857-64
pubmed: 21445972
Cancer. 2016 Dec 1;122(23):3641-3649
pubmed: 27648727
Ann Oncol. 2013 Jan;24(1):220-5
pubmed: 22898037
Oral Oncol. 2015 Apr;51(4):376-82
pubmed: 25593015
Lancet Oncol. 2019 Aug;20(8):1109-1123
pubmed: 31301962
Head Neck. 2015 Nov;37(11):1665-71
pubmed: 24954745
Lancet Oncol. 2009 Mar;10(3):247-57
pubmed: 19201650
Nat Rev Cancer. 2008 Aug;8(8):618-31
pubmed: 18633355